Futura Medical PLC Block Listing Six Monthly Return (1043W)
06 Diciembre 2019 - 10:10AM
UK Regulatory
TIDMFUM
RNS Number : 1043W
Futura Medical PLC
06 December 2019
Block Listing Six Monthly Return
6 December 2019
Futura Medical plc (AIM: FUM), a pharmaceutical company
developing a portfolio of innovative products for sexual health and
pain relief, makes the following update on its block listings,
pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for
Companies. All figures relate to options over Ordinary Shares of
0.2 pence each (Ordinary Shares).
Date: 6 December 2019
Name of applicant: Futura Medical Plc
Name of scheme: Unapproved Share Option Scheme
Unapproved Share Incentive Scheme
EMI Share Option Scheme
---------------------------------------
Period of return: From: 1 June 2019 To: 30 November 2019
------------------------ ------------- ---- ------------------
Balance of unallotted securities under scheme(s) from previous return: 6,225,000
---------------------------------------
Plus: The amount by which the block scheme(s) has been increased since the n/a
date of the last
return (if any increase has been applied for):
---------------------------------------
Less: Number of securities issued/allotted under scheme(s) during period: n/a
---------------------------------------
Equals: Balance under scheme(s) not yet issued/allotted at end of period: 6,225,000
---------------------------------------
Number and class of securities originally admitted and the date of admission USOS Total: 3,882,912
814,424 25 May 2011
1,202,280 8 October 2013
1,466,208 25 May 2017
400,000 30 May 2018
USIS Total: 425,000
425,000 30 November 2018
EMI Total: 7,012,088
1,520,576 25 May 2011
1,467,720 8 October 2013
1,893,792 25 May 2017
790,000 30 May 2018
1,340,000 30 November 2018
---------------------------------------
For further information please contact:
Futura Medical plc
James Barder, Chief Executive
Angela Hildreth, Finance Director and COO
Email: Investor.relations@futuramedical.com
Tel: +44 (0) 1483 685 670
Nominated Adviser and Sole Broker:
Liberum
Bidhi Bhoma/ Euan Brown
Tel: +44 (0) 20 3100 2000
For media enquiries please contact:
Optimum Strategic Communications
Mary Clark/ Eva Haas/ Hollie Vile
Email: futuramedical@optimumcomms.com
Tel: +44 (0) 203 950 9144
Notes to editors:
About Futura Medical plc
Futura Medical plc (AIM: FUM), is a pharmaceutical company
developing a portfolio of innovative products based on its
proprietary, transdermal Dermasys(R) drug delivery technology.
These products are optimised for clinical efficacy, safety,
administration and patient convenience and are developed for the
prescription and consumer healthcare markets as appropriate.
Current therapeutic areas are sexual health, including erectile
dysfunction, and pain relief. Development and commercialisation
strategies are designed to maximise product differentiation and
value creation whilst minimising risk.
The first European Phase 3 study for MED2005, referred to as
"FM57", is a 1,000 patient, dose-ranging, multi-centre, randomised,
double blind, placebo-controlled, home use, parallel group study of
MED2005 0.2%, 0.4% and 0.6% Glyceryl Trinitrate for the treatment
of erectile dysfunction with an open label extension. FM57 is
progressing on track, with headline data expected by the end of
2019.
Futura is based in Guildford, Surrey, and its shares trade on
the AIM market of the London Stock Exchange.
www.futuramedical.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BLRTFBFTMBMMBRL
(END) Dow Jones Newswires
December 06, 2019 11:10 ET (16:10 GMT)
Futura Medical (LSE:FUM)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Futura Medical (LSE:FUM)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
